期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

非小细胞肺癌患者ERCC1,β-tubulin Ⅲ的表达与TP/NP方案化疗敏感性关系分析 被引量：5

ERCC1 and Class Ⅲ β-tubulin Protein Expression in Relation to Tumour Response and Survival of Stage ⅢB/Ⅳ NSCLC Patients Treated with TP/NP Chemotherapy Regimens
下载PDF
导出
摘要 近20年来,随着第3代化疗新药（异长春花碱、紫杉类和吉西他滨等）在临床的广泛应用,以铂类为基础联合第3代化疗新药的方案已成为非小细胞肺癌（NSCLC）病人的标准化疗（SC）方案，但是化疗的反应率（RR）、总生存时间（OS）和肿瘤进展时间（TTP）仍然很低，而且不同NSCLC病人对同一种标准化疗方案疗效差异很大。
作者 肖永营 宋勇 施毅
机构地区 南京军区南京总医院呼吸科
出处 《中国肺癌杂志》 CAS 2009年第1期82-85,共4页 Chinese Journal of Lung Cancer
关键词 化疗敏感性 非小细胞肺癌 Β-TUBULIN ERCC1 肺癌患者 NP方案 标准化疗方案 异长春花碱
分类号 R734.2 [医药卫生—肿瘤]
  • 相关文献

参考文献6

  • 1Seve P,Dumontet C.Chemoresistance in non-small cell lung cancer.Curr Med Chem Anticancer Agents,2005,5(1):73-88.
  • 2Seve P,Mackey J,Isaac S,et al.Class Ⅲ beta-tubulin expression in tumor cells predicts response and outcome in patients with non-small cell lung cancer receiving paclitaxel.Mol Cancer Ther,2005,4(12):2001-2007.
  • 3Wachtersa FM,Wongb LSM,Timensc W,et al.ERCC1,hRad51 and BRCA1 protein expression in relation to tumour response and survival of stage Ⅲ/Ⅳ NSCLC patients treated with chemotherapy.Lung Cancer,2005,50(2):211-219.
  • 4Rosell R,Taron M,Barnadas A,et al.Nucleotide excision repair pathways involved in cisplatin resistance in non-small cell lung cancer.Cancer Control,2003,10 (4):297-305.
  • 5Urano N,Fujiwara Y,Doki Y,et al.Clinical significance of class-Ⅲ beta-tubulin expression and its predictive value for resistance to docetaxel-based chemotherapy in gastric cancer,Int Oncol,2006,28(2):375-381.
  • 6Seve P,Lai R,Ding K,et al.Class Ⅲβ -tubulin expression and benefit from adjuvant Cisplatin/Vinorelbine chemotherapy in operable nonsmall cell lung cancer:Analysis of NCIC JBR.10.Clin Cancer Bes,2007,13(3):994-999.

同被引文献44

  • 1Paul E.VAN SCHIL Michèle DE WAELE Jeroen M.HENDRIKS Patrick R.LAUWERS.Is there a role for surgery in stage ⅢA-N2 non-small cell lung cancer?[J].中国肺癌杂志,2008,11(5):615-621. 被引量：14
  • 2袁芃,缪小平,张雪梅,王中华,谭文,张湘茹,孙燕,徐兵河,林东昕.核苷酸切除修复系统基因遗传多态与晚期非小细胞肺癌患者铂类药物敏感性关系[J].癌症,2005,24(12):1510-1513. 被引量：46
  • 3Ikeda S, Takabe K, Suzuki K. Expression of ERCC1 and class Ⅲβ tubulin for predicting effect of Caboplatin/Paclitaxel in patients with advanced inoperable non-small cell lung cancer [ J ]. Pathol Int, 2009,59 (12) : 863-867.
  • 4Hayashi Y, Kuriyama H, Umezu H, et al. Class Ⅲ betatubulin expression in tumor cells is correlated with resistance to Docetaxel in patients with completely reseeted non-small-cell lung cancer [J]. Inter Med, 2009,48(4):203-208.
  • 5Seve P, Lai R, Ding K, et al. Class Ⅲ beta-tubulin expression and benefit from adjuvant Cisplatin/Vinorelbine chemotherapy in operable non-small cell lung cancer: Analysis of NCIC JBR. 10 [J]. Clin Cancer Res, 2007,13(3) :994-999.
  • 6Koh Y, Jang B, Han SW, et al. Expression of class Ⅲ beta- tubulin correlates with unfavorable survival outcome in patients with resected non-small cell lung cancer [J].J Thorac Oncol, 2010,5 (3) : 320-325.
  • 7Kamath K, Wilson L, Cabral F, et al. beta Ⅲ-tubulin induces Paclitaxel resistance in association with reduced effects on microtubule dynamic instability [J]. J Biol Chem, 2005,280 (13) : 12902-12907.
  • 8Hari M, Yang H, Zeng C, et al. Expression of class Ⅲ betatubulin reduces microtubule assembly and confers resistance to Paclitaxel [J ]. Cell Motil Cytoskeleton, 2003,56( 1 ):45-56.
  • 9Kavallaris M, Tait AS, Walsh B J, et al. Multiple microtubule alterations are associated with vinca alkaloid resistance in human leukemia cells [J ]. Cancer Res, 2001,61 (15) :5803- 5809.
  • 10Seve P, Reiman T, Dumontet C. The role of βⅢ tubulin in predicting chemoresistance in non-small cell lung cancer [J]. Lung Cancer, 2010,67(2) : 136-143.

引证文献5

二级引证文献27

中国肺癌杂志
2009年 第1期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部